Introduction

Over the past few decades, the treatment paradigm of gastrointestinal (GI) cancers has changed substantially. Monoclonal antibodies targeting angiogenesis and the epidermal growth factor receptor (EGFR) signaling pathway have become standard treatments for advanced colorectal cancers (CRCs) (1,2). Small molecule multikinase inhibitors have also demonstrated survival benefit in patients with refractory CRCs and hepatocellular carcinomas (HCCs) (3,4). Most recently, immunotherapy has shown promising clinical efficacy in multiple types of GI cancers (5,6). Although chemotherapy remains the mainstay of treatments for the majority of GI cancers, novel agents either as single agents or in combination are being evaluated in clinical trials at an accelerated pace. Here we review the major drugs that have demonstrated promising therapeutic activity in clinical trials. Immunotherapy is not a significant part of the discussion here as it is discussed in great detail in another review in this issue.

Growth signaling pathway inhibitors

Inhibition of growth signaling pathways has traditionally been a research hot spot for GI cancers, and it has achieved significant success with the development and clinical use of small molecule kinase inhibitors and monoclonal antibodies (1,2,4). Strategies of inhibiting the growth factor pathways include targeting cell surface receptors or their downstream cellular cascades. Vascular endothelial growth factor receptor (VEGFR), MET, c-kit, platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) are commonly targeted cell surface receptors. Activation of these receptors stimulates various downstream signaling pathways that promote tumor cell proliferation and sustain cell survival. One of the pathways...
commonly involved is the Raf-MEK-ERK mitogen-activated protein kinase (MAPK) cascade, in which activated Raf kinases phosphorylate the downstream MEK kinases, and the latter activate the extracellular signal-regulated kinases (ERK), which lead to cell growth (Figure 1) (7). Therapeutics targeting the above cell surface receptors and the downstream Raf-MEK-ERK pathway have shown some promising results in GI cancers in early phase clinical studies.

Cabozantinib is a dual inhibitor of the cell surface growth receptors VEGFR2 and MET. In a phase II study, patients with advanced HCCs were treated with cabozantinib at 100 mg daily for 12 weeks as the lead-in stage (8). Patients who demonstrated partial response (PR) were continued on the treatment, whilst those with stable disease (SD) were randomized to continue receiving cabozantinib or placebo. Among the 41 patients enrolled, half had received prior sorafenib. Cabozantinib was frequently associated with fatigue, diarrhea, hand-foot syndrome, nausea/vomiting, and thrombocytopenia. Sixty percent of patients needed dose reductions during the lead-in stage. The overall response rate (ORR) was 5%, but 78% of patients had SD. The median progression-free survival (PFS) was 4.4 months, and the median overall survival (OS) was 15.1 months. These results were encouraging given that historically, the ORR and the median OS for untreated HCC patients

Figure 1 Commonly targeted growth factor signaling pathways.
who received sorafenib were only 2% and 10.7 months, respectively (4). A phase III study evaluating cabozantinib at a dose of 60 mg daily versus placebo in patients with advanced HCC who have received prior sorafenib is ongoing (NCT01908426).

Another multitargeted kinase inhibitor, regorafenib, targets multiple cell surface growth signaling receptors including VEGFR1-3, KIT, PDGFR, and FGFR. It has been approved for the treatment of advanced CRC. Recent data indicated that it is also effective in treating advanced HCC. The phase III RESORCE study tested the efficacy of regorafenib in patients with HCC who had progressed on sorafenib. The results were presented at the European Society for Medical Oncology (ESMO) World Congress of Gastrointestinal Cancer 2016 (9). A total of 573 patients were randomized 2:1 to receive regorafenib at 160 mg for 3 weeks every 4-week cycle versus placebo. Severe adverse events were experienced in 79.7% of patients treated with regorafenib versus 58.5% of those received placebo. Common adverse events of regorafenib included hypertension, hand-foot syndrome, fatigue, and diarrhea. Regorafenib significantly improved the ORR (10.6% vs. 4.1%; P<0.005), PFS (3.1 vs. 1.5 months; HR 0.46; 95% CI: 0.37–0.56; P<0.001), and OS (10.6 vs. 7.8 months; HR 0.62; 95% CI: 0.50–0.78; P<0.001) compared to placebo. These results are very encouraging and make regorafenib an attractive agent for HCC patients progressed on sorafenib.

Similar to regorafenib, nintedanib is also a multitargeted inhibitor targeting VEGFR1–3, FGFR, and PDGFR, but with a better toxicity profile. In a phase I study, 30 patients with previously treated advanced CRC were treated with nintedanib (10). This was a heavily pretreated population with prior lines of treatment ranging from 1–5. Nintedanib was well tolerated with the most common adverse events being mild nausea, vomiting, and diarrhea. Only 10% of patients had ≥ grade 3 toxicities. Twenty-four patients (80%) had SD for ≥28 weeks, and one patient had PR. Compared to regorafenib, which provided a SD rate of 40% and a PR rate of 1% but caused ≥ grade 3 toxicities in more than half of patients (3), nintedanib was much better tolerated and seemed to be quite active in refractory CRCs. The phase III LUME-Colon 1 trial is comparing nintedanib with placebo in patients with previously treated metastatic CRC (NCT02149108). This study has finished accrual of 764 patients and was estimated to be completed in December 2016.

There has been quite a lot of excitement in targeting FGFR, particularly in cholangiocarcinoma. The FGFR family consists of four receptors that are activated by binding fibroblast growth factors using heparin or heparin sulfate proteoglycan as a co-factor (11). Activated FGFR triggers complex downstream pathways including the phosphoinositide 3-kinase (PI3K)-AKT cascades and the Raf-MEK-ERK signaling pathway. FGFR2 fusions have been identified in approximately 13% of intrahepatic cholangiocarcinomas (12,13). Preliminary efficacy of FGFR inhibitors has been demonstrated in patients with FGFR2 fusion and preclinical models (14,15). A phase II study examined the activity of a pan-FGFR inhibitor, BGJ398, in patients with previously treated advanced cholangiocarcinoma harboring FGFR2 alterations (16). Forty-seven patients received the study drug. FGFR2 translocations were found in 38 patients, with FGFR2-BICC1 fusions being the most common (n=9). Nine patients had other FGFR alterations, including mutations in FGFR and amplifications in FGFR2 and FGFR3. This was a heavily pretreated patient population, with 62% of patients receiving ≥2 prior lines of therapies, and 11% with ≥4 prior regimens. Adverse events were overall manageable, with hyperphosphatemia, fatigue, constipation, and diarrhea being the most common. Among a total of 36 evaluable patients, eight patients (22%) had PR and 19 (53%) had SD. Median duration of drug exposure was 188 days. These results were encouraging when compared to the median PFS of approximately 3 months in patients who received second-line therapies for advanced cholangiocarcinoma (17,18). Several clinical studies are ongoing to test the role of other FGFR inhibitors in cholangiocarcinomas or other solid tumors harboring FGFR alterations (NCT02834780, NCT01752920).

Moving from the cell surface receptors to downstream signaling cascades, the Raf-MEK-ERK signaling pathway is frequently involved in carcinogenesis. The BRAF gene encodes an intracellular Raf protein, which upon activation, phosphorylates and triggers sequential activation of the MEK/ERK protein cascade. BRAF mutations occurred in approximately 12% of CRCs (19). Patients with metastatic BRAF-mutant CRCs have a worse survival compared to their BRAF wild type counterparts, with a median survival of approximately one year (20). In contrast to the potent activity of the BRAF inhibitor vemurafenib in melanoma, single-agent vemurafenib failed in a phase II study of patients with metastatic BRAF-mutated CRCs, with an ORR of 5% and a median PFS of 2.1 months (21). This indicated that the BRAF inhibition alone might not be sufficient in treating BRAF-mutant CRCs, and combination...
therapy might be a better treatment approach. In a phase II study, investigators examined the combination of a BRAF inhibitor, encorafenib, and the anti-EGFR antibody, cetuximab, with or without the PI3Ka inhibitor, alpelisib, in patients with previously treated advanced CRCs that are BRAF-mutated (22). A total of 102 patients were randomized to the triplet versus the doublet arm. Grade 3–4 adverse events including anemia, hyperglycemia, and elevated lipase were more common in the triplet arm. The ORR was 27% for the triplet arm versus 22% for the doublet arm. Both median PFS (5.4 months for triplet versus 4.2 months for doublet; HR 0.8; 95% CI: 0.5–1.2; P=0.14) and median OS were similar between the two arms (13.1 months for triplet versus 12.4 months for doublet; HR 1.1; 95% CI: 0.6–2.0). The median OS in this study was much better compared to the historical OS of approximately 6 months for this patient population (23,24), but the survival benefit needs to be confirmed in phase III clinical trials. Furthermore, whether the survival benefit with additional alpelisib outweighs the increased toxicities awaits further examination in future studies.

Further down the Raf-MEK-ERK pathway, small molecule kinase inhibitors targeting the MEK protein, such as cobimetinib and trametinib, have prolonged survival in patients with BRAF-mutant melanoma (25,26). Ongoing efforts are examining the role of MEK inhibitors in CRC. A phase Ib study tested the combination of cobimetinib with the PD-L1 inhibitor atezolizumab in patients with microsatellite stable CRCs. Single agent PD-1 blockade does not appear to have significant anti-tumor activity in microsatellite stable tumors (5). Inhibiting MEK with cobimetinib upregulates the major histocompatibility complex (MHC) class I on tumor cells, enhances intratumoral T cell filtration, and increases the activity of atezolizumab (27). In this study, a total of 23 patients received cobimetinib and atezolizumab (28). This was a heavily pretreated patient population, with a median of three lines of prior therapies. The microsatellite status was stable in 30% of patients and unknown in the other 70%. There were no dose-limiting toxicities (DLTs) observed with the maximum dose of cobimetinib at 60 mg daily. The most common adverse events included diarrhea, fatigue, rash, pruritus, and nausea. One third of patients experienced grade 3 toxicities, with diarrhea being the most common. But there were no grade 4 or 5 toxicities. The ORR was 17%, and the duration of response was not reached (range, 5.4 to 11.1+ months) by the time results were presented. The 6-month PFS and OS rates were 35% and 72%, respectively. Again, compared to the historical ORR of 1% and median PFS of approximately 2 months in patients with refractory CRCs, these results looked extremely promising (3). Based on these data, a phase III study investigating the activity of cobimetinib plus atezolizumab in patients with chemotherapy-refractory advanced CRCs is ongoing (NCT02788279).

**Targeting the tumor microenvironment**

The tumor microenvironment is a complex network comprised of extracellular matrix (ECM) and a myriad of immune cells. It serves as a mechanical and biochemical barrier that shields off the delivery and/or attenuates the antitumor effect of drugs, and more importantly, creates an immunosuppressive environment that impedes tumor immune response. Drugs targeting the tumor microenvironment have been aimed at different facets of the network, including the pro-tumorigenic cytokine signaling pathways such as transforming growth factor-β (TGF-β) and CC chemokine ligand 2-CC chemokine receptor 2 (CCL2-CCR2), enzymes or transmembrane proteins that modulate T cell activities such as indoleamine-2,3-dioxygenase (IDO) and CD40, and the mechanical component of the tumor stroma such as hyaluronan (HA).

The TGF-β cytokine is secreted by tumors and, in turn, facilitates tumor progression and invasion. TGF-β upregulates VEGF and promotes angiogenesis, suppresses the antitumor effect of T cells and natural killer (NK) cells, and stimulates the production of metalloproteinases (MMPs) that degrade ECM and facilitate tumor invasion (29). The TGF-β receptor-1 kinase inhibitor galunisertib was tested in a phase II study in patients with advanced HCC who had progressed on or were ineligible for sorafenib (30). A total of 109 HCC patients with Child Pugh A or B7 disease were randomized to receive galunisertib at 160 or 300 mg/day on a 2-week on, 2-week off schedule. Twenty-four percent of patients had a reduction in serum alpha fetoprotein (AFP) levels by >20% from baseline. The median time-to-progression (TTP) and OS were 2.8 and 8.3 months in the overall population, and 4.3 and 21.4 months in the AFP responders, respectively. Galunisertib was well tolerated at both dose levels. Neutropenia, fatigue, and anemia were the most common grade 3–4 adverse events. The 300 mg/day dose was found to confer better drug exposure, and it was selected for future studies. Another phase II study tested galunisertib in patients with advanced HCC but low serum AFP levels (31). The majority of patients had received
prior sorafenib. Twenty-nine out of 40 patients treated with galunisertib had a reduction in serum TGF-β levels by >20%. In patients with a TGF-β reduction >20%, the median OS was 21.8 months, compared to 7.9 months in those without a TGF-β response. Combinations of galunisertib and immunotherapy are being evaluated in patients with HCC (NCT02423343) and pancreatic cancer (NCT02734160). The incorporation of galunisertib into neoadjuvant chemoradiotherapy is also being explored in locally advanced rectal cancer in a phase II study (NCT02688712).

The CCL2-CCR2 chemokine signaling pathway has been avidly studied as a target for anticancer therapies. Tumors and stromal cells synthesize the CCL2 ligand, which recruits CCR2-positive inflammatory monocytes to the tumors, where they can differentiate into immunosuppressive tumor-associated macrophages (TAMs) (32, 33). TAMs play an important role in mediating tumor immune evasion and promoting tumor progression and invasion (34,35). High CCL2 expression and low CD8+ T cell infiltrates in the tumors was associated with decreased survival in patients who underwent resection of pancreatic cancers (36). A phase Ib study tested the combination of the CCR2 inhibitor PF-04136309 with FOLFIRINOX in patients with borderline resectable or locally advanced pancreatic cancers. This combination regimen resulted in an ORR of 49% and a disease control rate of 97% (37). PF-04136309 was generally well tolerated. These results looked promising in light of the ORR of 32% and the disease control rate of 70% with FOLFIRINOX alone (38). A phase I study testing the combination of PF-04136309 with gemcitabine and nab-paclitaxel in pancreatic cancer is ongoing (NCT02732938). Another CCR2 inhibitor, CCX872-B, is being tested in a phase Ib study in combination with FOLFIRINOX in patients with advanced pancreatic cancers (NCT02345408).

Apart from the chemokine signaling pathways, T cells are also major components of the tumor microenvironment and are critical in tumor-specific immune responses. Most tumors evade this immune surveillance by a plethora of mechanisms, one of which being the IDO pathway. IDO is the key enzyme in the catabolism of tryptophan that is critical in the differentiation and proliferation of T cells. Both tumors and antigen-presenting cells (APCs) express IDO, which suppresses tumor-specific cytotoxic T cells and enhances the activity of immunosuppressive regulatory T cells (39). In a breast cancer mouse model, an IDO inhibitor in combination with paclitaxel synergistically induced tumor regression (40). A phase I/II study examined the combination of an IDO inhibitor, indoximod, with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. In this study, five out of 12 patients achieved an objective response (42%), including one patient with a complete response (41). The combination was well tolerated, with common side effects being fatigue, weight loss, diarrhea, and peripheral edema. An interim analysis of the phase II part of this study continued to confirm the efficacy, with 11 out of 30 patients demonstrating an objective response (37%) (42). Given that the ORR with gemcitabine plus nab-paclitaxel was 23% (43), incorporating indoximod into this regimen may provide additional clinical benefits. This study remains ongoing to further examine the role of indoximod in the treatment of pancreatic cancers (NCT02077881).

Another means to activate cytotoxic T cells is via the ligation of the transmembrane protein CD40. CD40 is a member of the tumor necrosis factor (TNF) superfamily. It is widely expressed on APCs and a variety of tumors (44,45). Ligation of CD40 on APCs orchestrates the priming and activation of tumor-specific cytotoxic T cells and eradicates tumors (46,47). CD40 ligation on carcinoma cells also upregulates the expression of Fas and TNF in these cells and induces apoptosis (48). A phase I study examined the combination of an agonist CD40 monoclonal antibody, CP-870,893, with gemcitabine in patients with untreated advanced pancreatic cancers (49). Four out of 22 patients achieved a PR (18%). The combination was generally well-tolerated, with mild cytokine release syndrome, fatigue, and cytopenia being the most common adverse events. Phase I studies are ongoing to evaluate several CD40 agonistic antibodies either alone or in combination with immunotherapy in patients with solid tumors. Other CD40 antibodies under investigation include APX005M (NCT02482168), SEA-CD40 (NCT02376699), and RO7009789 (NCT02665416, NCT02304393).

Besides the signaling pathways that modify immune responses, the tumor stroma itself can also be a therapeutic target. This is particularly important in pancreatic cancer, which is surrounded by a desmoplastic stroma enriched with HA. There was some preclinical evidence suggesting that HA stimulated pancreatic cancer cell migration (50). High expressions of HA in the tumors were associated with shorter survival in patients with resected pancreatic cancer (51). A PEGylated recombinant human hyaluronidase, PEGPH20, depletes HA and was tested in a randomized phase II trial (52). In this study, patients with untreated
metastatic pancreatic cancers were randomly assigned to receive nab-paclitaxel plus gemcitabine with or without PEGPH20. A total of 135 patients received at least one dose of the study drugs. In all patients, the ORR (with vs. without PEGPH20: 41% vs. 34%; P=0.48) and PFS (with vs. without PEGPH20: 5.7 vs. 5.2 months; P=0.11) were similar. However, in those with high expressions of HA, the ORR was better in the PEGPH20 arm (52% vs. 41%; P=0.038). The PEGPH20 arm also showed a trend towards longer PFS (9.2 vs. 4.3 months; HR 0.39; 95% CI: 0.15–1.04; P=0.05) and better OS (12 vs. 9 months; HR 0.62; 95% CI: 0.26–1.46). The PEGPH20 group experienced more thromboembolic events, peripheral edema, muscle spasms, and neutropenia, but these toxicities were manageable and the incidence of thromboembolic events decreased substantially after prophylactic enoxaparin was implemented. A phase III study evaluating the efficacy of PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with HA-high metastatic pancreatic cancers is ongoing (NCT02715804).

Cancer stemness inhibitor

Cancer stem cells are referred to the subpopulations of cancer cells harboring extremely high potential for tumorigenesis and have been isolated from various GI cancers (53–55). Napabucasin (BBI-608) is a first-in-class cancer stemness inhibitor that targets Stat3-dependent gene transcription. In a phase Ib study, napabucasin was tested in combination with FOLFIRI and bevacizumab in patients with advanced CRCs (56). A total of 46 patients were enrolled and randomized to receive napabucasin plus FOLFIRI with or without bevacizumab. There were no DLTs observed in the study, and the most common grade 3 adverse events were diarrhea and fatigue. An objective response was achieved in 13 of the 40 evaluable patients (33%). Furthermore, among the 14 evaluable patients who were previously refractory to FOLFIRI, three achieved PR (25%). These results are intriguing and suggest that a cancer stemness inhibitor may re-sensitize refractory patients to chemotherapy. A phase III study of napabucasin is ongoing in patients with advanced CRCs (NCT02753127).

Other novel targets for GI cancer treatment

IMAB362 is a first-in-class monoclonal antibody against the tight junction protein claudin 18.2 (CLDN18.2), which is frequently expressed on gastric cancers (57). In the phase II FAST trial, patients with CLDN18.2-positive advanced gastric or gastroesophageal junction (GEJ) cancers were randomized 1:1 to receive epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362 (58). A total of 161 patients were randomized. IMAB362 plus chemotherapy significantly improved the median PFS (7.9 vs. 4.8 months; HR 0.47; 95% CI: 0.31–0.70; 1-sided P=0.0001) and OS (13.2 vs. 8.4 months; HR 0.51; 95% CI: 0.36–0.73; P=0.0001). Moreover, IMAB362 seemed to be more beneficial in those who had high expressions of CLDN18.2, defined as 2+ or 3+ CLDN18.2 expression in ≥70% of tumor cells. In these patients, the median OS with and without IMAB362 were 16.7 and 9.0 months (HR 0.45; P≤0.0005), respectively. Also of note, in this study, patients treated with EOX alone only had a median OS of 8.4 months, which was inferior to the median OS of 11.2 months with EOX in the REAL-2 trial (59). Incorporating IMAB362 with a better chemotherapy backbone may be worthy of investigation in future clinical studies.

Conclusions

Novel drugs targeting various antitumor mechanisms of GI cancers are under rapid development (Table 1). Inhibitors targeting growth factor pathways have shown encouraging results in early phase studies. By targeting cell surface receptors, the multikinase inhibitors cabozantinib and regorafenib have demonstrated significant clinical activity in advanced HCCs, and both are being tested in phase III studies. FGFR inhibitors may alter the treatment paradigm of cholangiocarcinoma with FGFR translocations. Agents targeting different levels of the cellular Raf–MEK–ERK signaling pathway are also being tested in GI cancers. In BRAF mutant CRCs, the combination of the BRAF inhibitor encorafenib and cetuximab has demonstrated promising efficacy and warrants further study in phase III trials. The MEK inhibitor cobimetinib seems to enhance the antitumor activity of PD-L1 inhibitor in patients with microsatellite stable CRCs. Drugs that modify the immunosuppressive tumor microenvironment seem to be active against GI cancers, but may need to be combined with other drugs such as chemotherapy or immunotherapy to enhance the antitumor effect. These agents include the TGF-β inhibitor galunisertib, CCR2 inhibitors PF-04136309 and CCX872-B, the IDO inhibitor indoximod, the CD40 agonizing antibody CP-870,893, and the recombinant hyaluronidase PEGPH20. Last but not least, drugs aimed at novel targets are breaking new ground in the
<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Study arms</th>
<th>Disease type</th>
<th>Phase</th>
<th>NCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabozantinib</td>
<td>Multi: MET, VEGFR2</td>
<td>Cabozantinib vs. placebo</td>
<td>HCC</td>
<td>III</td>
<td>01908426</td>
</tr>
<tr>
<td>Regorafenib</td>
<td>Multi: VEGFR1–3, KIT, PDGFR, FGFR</td>
<td>Regorafenib vs. placebo</td>
<td>HCC</td>
<td>III</td>
<td>01774344</td>
</tr>
<tr>
<td>Nintedanib</td>
<td>Multi: VEGFR1–3, PDGFR, FGFR</td>
<td>Nintedanib vs. placebo</td>
<td>CRC</td>
<td>III</td>
<td>02149108</td>
</tr>
<tr>
<td>BGJ398</td>
<td>FGFR inhibitor</td>
<td>BGJ398</td>
<td>Cholangiocarcinoma</td>
<td>II</td>
<td>02150967</td>
</tr>
<tr>
<td>Encorafenib</td>
<td>BRAF inhibitor</td>
<td>Encorafenib + cetuximab +/- PI3Kα inhibitor alpelisib</td>
<td>BRAF mutant CRC</td>
<td>II</td>
<td>01719380</td>
</tr>
<tr>
<td>Cobimetinib</td>
<td>MEK inhibitor</td>
<td>Cobimetinib + atezolizumab vs. atezolizumab vs. regorafenib</td>
<td>CRC</td>
<td>III</td>
<td>02788279</td>
</tr>
<tr>
<td>Galunisertib</td>
<td>TGF-β inhibitor</td>
<td>Galunisertib + durvalumab</td>
<td>Pancreatic cancer</td>
<td>I</td>
<td>02734160</td>
</tr>
<tr>
<td>Galunisertib</td>
<td>TGF-β inhibitor</td>
<td>Galunisertib + nivolumab</td>
<td>HCC</td>
<td>I/II</td>
<td>02423343</td>
</tr>
<tr>
<td>Galunisertib</td>
<td>TGF-β inhibitor</td>
<td>Galunisertib + fluorouracil-based chemoradiotherapy + surgery</td>
<td>Rectal cancer</td>
<td>II</td>
<td>02688712</td>
</tr>
<tr>
<td>PF-04136309</td>
<td>CCR2 inhibitor</td>
<td>PF-04136309 + gemcitabine + nab-paclitaxel</td>
<td>Pancreatic cancer</td>
<td>I</td>
<td>02732938</td>
</tr>
<tr>
<td>CCX872-B</td>
<td>CCR2 inhibitor</td>
<td>CCX872-B + FOLFIRINOX</td>
<td>Pancreatic cancer</td>
<td>Ib</td>
<td>02345408</td>
</tr>
<tr>
<td>PEGPH20</td>
<td>Hyaluronidase</td>
<td>Gemcitabine + nab-paclitaxel +/- PEGPH20</td>
<td>Hyaluronan-high pancreatic cancer</td>
<td>III</td>
<td>02715804</td>
</tr>
<tr>
<td>Napabucasin</td>
<td>Cancer stemness inhibitor</td>
<td>FOLFIRI +/- napabucasin. Bevacizumab allowed in both arms</td>
<td>CRC</td>
<td>III</td>
<td>02753127</td>
</tr>
<tr>
<td>IMAB362</td>
<td>CLDN18.2 inhibitor</td>
<td>Epirubicin + capecitabine + oxaliplatin + IMAB362</td>
<td>CLDN18.2+ gastric cancer</td>
<td>II</td>
<td>01630083</td>
</tr>
</tbody>
</table>

Multi, multikinase inhibitor; VEGFR, vascular endothelial growth factor receptor; vs., versus; HCC, hepatocellular carcinoma; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; CRC, colorectal cancer; TGF-β, transforming growth factor-β; CCR2, CC chemokine receptor 2; CLDN18.2, claudin 18.2.
treatment of GI cancers. The first-in-class cancer stemness inhibitor napabucasin in combination with chemotherapy has shown encouraging activity in patients with advanced CRCs and may overcome the problem of chemotherapy refractoriness in those who are heavily pretreated. In addition, the CLDN18.2 inhibitor IMAB362 is active against CLDN18.2-positive gastric cancers. Selecting the correct patient population and incorporating IMAB362 with better chemotherapy regimens would be the key for future studies.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


J Gastrointest Oncol 2017;8(3):524-533.

Cite this article as: Du L, Che Z, Wang-Gillam A. Promising therapeutics of gastrointestinal cancers in clinical trials. J Gastrointest Oncol 2017;8(3):524-533. doi: 10.21037/jgo.2017.01.08